🚀 VC round data is live in beta, check it out!
Balchem Valuation Multiples
Discover revenue and EBITDA valuation multiples for Balchem and similar public comparables like Syensqo, Fertiglobe, Bachem, SICC and more.
Balchem Overview
About Balchem
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Founded
1967
HQ
Employees
1.4K
Website
Financials (LTM)
EV
$6B
Balchem Financials
Balchem reported last 12-month revenue of $1B and EBITDA of $279M.
In the same LTM period, Balchem generated $376M in gross profit, $279M in EBITDA, and $158M in net income.
Revenue (LTM)
Balchem P&L
In the most recent fiscal year, Balchem reported revenue of $1B and EBITDA of $275M.
Balchem expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $376M | XXX | $371M | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBITDA | $279M | XXX | $275M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $158M | XXX | $155M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | — | — | $89M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Balchem Stock Performance
Balchem has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
Balchem's stock price is $182.47.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | 0.0% | XXX | XXX | XXX | $4.84 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBalchem Valuation Multiples
Balchem trades at 5.7x EV/Revenue multiple, and 21.4x EV/EBITDA.
EV / Revenue (LTM)
Balchem Financial Valuation Multiples
As of March 17, 2026, Balchem has market cap of $6B and EV of $6B.
Equity research analysts estimate Balchem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Balchem has a P/E ratio of 36.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 21.4x | XXX | 21.6x | XXX | XXX | XXX |
| EV/EBIT | 27.6x | XXX | 28.1x | XXX | XXX | XXX |
| EV/Gross Profit | 15.8x | XXX | 16.1x | XXX | XXX | XXX |
| P/E | 36.9x | XXX | 37.7x | XXX | XXX | XXX |
| EV/FCF | 36.7x | XXX | 34.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Balchem Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Balchem Margins & Growth Rates
Balchem's revenue in the last 12 month grew by 6%.
Balchem's revenue per employee in the last FY averaged $0.8M.
Balchem's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Balchem's rule of X is 41% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Balchem Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Balchem Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals and Chemicals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Syensqo | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Bachem | XXX | XXX | XXX | XXX | XXX | XXX |
| SICC | XXX | XXX | XXX | XXX | XXX | XXX |
| Croda International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Balchem M&A Activity
Balchem acquired XXX companies to date.
Last acquisition by Balchem was on XXXXXXXX, XXXXX. Balchem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Balchem
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBalchem Investment Activity
Balchem invested in XXX companies to date.
Balchem made its latest investment on XXXXXXXX, XXXXX. Balchem invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Balchem
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Balchem
| When was Balchem founded? | Balchem was founded in 1967. |
| Where is Balchem headquartered? | Balchem is headquartered in United States. |
| How many employees does Balchem have? | As of today, Balchem has over 1K employees. |
| Who is the CEO of Balchem? | Balchem's CEO is Theodore L. Harris. |
| Is Balchem publicly listed? | Yes, Balchem is a public company listed on Nasdaq. |
| What is the stock symbol of Balchem? | Balchem trades under BCPC ticker. |
| When did Balchem go public? | Balchem went public in 1986. |
| Who are competitors of Balchem? | Balchem main competitors are Syensqo, Fertiglobe, Bachem, SICC. |
| What is the current market cap of Balchem? | Balchem's current market cap is $6B. |
| What is the current revenue of Balchem? | Balchem's last 12 months revenue is $1B. |
| What is the current revenue growth of Balchem? | Balchem revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Balchem? | Current revenue multiple of Balchem is 5.7x. |
| Is Balchem profitable? | Yes, Balchem is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Balchem? | Balchem's last 12 months EBITDA is $279M. |
| What is Balchem's EBITDA margin? | Balchem's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Balchem? | Current EBITDA multiple of Balchem is 21.4x. |
| What is the current FCF of Balchem? | Balchem's last 12 months FCF is $162M. |
| What is Balchem's FCF margin? | Balchem's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Balchem? | Current FCF multiple of Balchem is 36.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.